Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®

Authors

Institutions

Publication Details

Journal
Drugs in R&D
Published
2024-09-01
DOI
https://doi.org/10.1007/s40268-024-00485-3
Citations
6
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
1.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®

Florian Wolschin, Steffen Jakob, Jakob C. Stüber, A. Reiter et al.
6 citations
Drugs in R&D
Biosimilars and Bioanalytical Methods
1.44
article

Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda®

Florian Wolschin, Steffen Jakob, Jakob C. Stüber, A. Reiter, Kerstin Uhland
article en
6 citations

Abstract

No abstract available for this paper.
Drugs in R&DVol. 24(3)
MorphoSys (Germany) (DE), Center for Human Genetics (US)
Zero hunger
Openalex Percentile: Top 18%
Biosimilars and Bioanalytical Methods
1.44
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Comparative Analytical Evaluation of the Proposed Biosimilar FYB206 and its Reference Medicinal Product Keytruda® — Florian Wolschin, Steffen Jakob, et al. · Drugs in R&D (2024) | TGRS Research Map | TGRS